OKUR
OnKure Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.59 EPS, $170K rev
Last earnings -1.7% on 2026-05-05
$4.50
▲ +6.64%$4.50▲ +86.72%
over 1Y
L $2.00EODHDH $5.27
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.6%
1W+1.4%
1M+9.8%
3M+12.8%
YTD+52.0%
1Y+86.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Conservative balance sheet (liabilities/equity 0.11x).
Revenue (FY2024) $0.00 · FY2024
OnKure Therapeutics, Inc. shows $0.00 in FY2024 revenue, and -105.9% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$39.8M | -$53.8M | -$36.9M | -$54.4M | -$63.0M |
| Net income | -$39.8M | -$52.0M | -$35.3M | -$52.7M | -$59.5M |
| Diluted EPS | -$2.19 | -$2.12 | -$124.41 | -$15.28 | -$4.40 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.48M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-96.7%
FCF yield-84.3%
Quality & risk
ROIC (est.)-88.5%
Free cash flow-$51.9M
Total debt—
Net cash$59.0M
Altman Z-Score-0.89 distress
Piotroski F-Score2/6
Capital returns
Buyback yield7.2%
Dividend yield (est.)—
Shareholder yield7.2%
Shares Δ YoY-59.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-04
- 8-K Earnings results2026-05-05
- 10-Q Quarterly report2026-05-05
- S-3 Shelf registration (potential raise)2026-04-24
- DEF 14A Proxy statement2026-04-21
- 8-K Officer / director change2026-03-30
- 8-K Earnings results2026-03-12
- 10-K Annual report2026-03-12
- 8-K Material agreement2025-11-06
Recent filings
all on EDGAR ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗S-8Filing2026-06-05open ↗8-KPeriod ending 2026-06-032026-06-04open ↗SCHEDULE 13GFiling2026-05-27open ↗SCHEDULE 13G/AFiling2026-05-15open ↗
Frequently asked
- Is OnKure Therapeutics, Inc. (OKUR) a buy?
- OKUR currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.11x).
- What is OnKure Therapeutics, Inc.'s quality score?
- OKUR scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001637715, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 6:58:52 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.